RM-DIA / Diagnostic and conjugated peptide agents
Lutetium Lu 177 Dotatate
Also known as: Lutathera · 177Lu-DOTATATE · Lutetium oxodotreotide
Grade describes the published research on the molecule. It is not a quality score, a safety score, or a release state.
What this is
Lutetium Lu 177 dotatate combines a somatostatin-receptor peptide ligand, DOTA chelator and lutetium-177 radionuclide. All three parts define the material.
Evidence position
The regulated radiopharmaceutical and human evidence support Grade A for the complete labeled product.
What the record does not establish
The label does not authenticate unlabelled DOTA-TATE, another isotope, a different activity or a separately prepared conjugate.
Sources
- 01Lutathera prescribing informationDailyMed / U.S. National Library of Medicine
- Shows
- Current U.S. label for a defined lutetium-177 dotatate intravenous product
- Does not show
- Does not qualify unlabeled peptide, another isotope, activity, chelator or formulation
External database index
LIVE DATABASE INDEX / SEPARATE FROM CURATED EVIDENCE
Records below come directly from public scientific databases. They help find relevant material, but do not affect the evidence grade until they are matched to the molecule and added to the curated source list.
PUBMED / FOUND RECORDS
- (177)Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors.Expert review of gastroenterology & hepatology / 2019 NovPMID 31652074 / DOI 10.1080/17474124.2019.1685381
- Lutetium Lu 177 Dotatate. / 2006PMID 30000023
- Lutetium Lu-177 Dotatate Flare Reaction.Advances in radiation oncology / 2021 Jan-FebPMID 33490736 / DOI 10.1016/j.adro.2020.11.008
- Pheochromocytomas and paragangliomas.Current opinion in pediatrics / 2021 Aug 1PMID 34039901 / DOI 10.1097/MOP.0000000000001029
- Evaluation of the SSTR2-targeted Radiopharmaceutical 177Lu-DOTATATE and SSTR2-specific 68Ga-DOTATATE PET as Imaging Biomarker in Patients with Intracranial Meningioma.Clinical cancer research : an official journal of the American Association for Cancer Research / 2024 Feb 16PMID 38048045 / DOI 10.1158/1078-0432.CCR-23-2533
CLINICALTRIALS.GOV / FOUND RECORDS
- Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine CellsRECRUITING / PHASE2 / National Cancer Institute (NCI)NCT05691465 / DIRECT intervention MATCH: Lutetium Lu 177 Dotatate
- A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and AtezolizumabACTIVE_NOT_RECRUITING / PHASE1, PHASE2 / Novartis PharmaceuticalsNCT05142696 / DIRECT intervention MATCH: Lutetium Lu 177 Dotatate
- Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE in Advanced Gastro-entero Pancreatic Neuroendocrine TumorsTERMINATED / PHASE2 / Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSNCT02489604 / DIRECT intervention MATCH: "177Lu-DOTATATE"
- A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine TumoursSUSPENDED / PHASE2 / AHS Cancer Control AlbertaNCT01876771 / DIRECT intervention MATCH: "177Lu-DOTATATE"
- Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors.RECRUITING / PHASE1 / Emory UniversityNCT07150546 / DIRECT intervention MATCH: Lutetium Lu 177 Dotatate